Alex McKeown

Alex McKeown

Company: Apellis

Job title: Director of Translational Ophthalmology

Seminars:

Panel Discussion: Future Directions for Anti-VEGF Therapies 12:10 pm

Increasing patient response rates, not just prolonging treatment duration New therapy formats (bispecifics) – how does dual-specificity open up a wide range of therapeutic applications for these multifactorial diseases? Combinatorial approaches – approaches that could potentially be used on patients currently refractory or not optimally treated with anti-VEGF-A therapy aloneRead more

day: Day One

Developing a Bispecific anti-VEGF/Complement C3 Inhibitor to Treat nAMD & Macular Atrophy 11:00 am

Wet AMD patients with anti-VEGF therapies develop geographic atrophy A combination of VEGF and C3 inhibition may result in superior outcome in wet AMD patients Novel endpoints are needed to assess the functional benefits of GA therapiesRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.